FEATURED COMPANIES
- Biological E. Ltd.
- GlaxoSmithKline plc
- Instituto Butantan
- Panacea Biotec Ltd.
- Sanofi SA
- Vabiotech
Global Dengue Vaccine Market to Reach $962.1 Million by 2027
Amid the COVID-19 crisis, the global market for Dengue Vaccine estimated at US$340 Million in the year 2020, is projected to reach a revised size of US$962.1 Million by 2027, growing at a CAGR of 16% over the analysis period 2020-2027. Government Institutions, one of the segments analyzed in the report, is projected to record a 15.2% CAGR and reach US$490.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hospitals segment is readjusted to a revised 16.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $97.8 Million, While China is Forecast to Grow at 20.9% CAGR
The Dengue Vaccine market in the U.S. is estimated at US$97.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$193.1 Million by the year 2027 trailing a CAGR of 20.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.6% and 14.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.8% CAGR.
NGOs Segment to Record 17.6% CAGR
In the global NGOs segment, USA, Canada, Japan, China and Europe will drive the 16.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$38.8 Million in the year 2020 will reach a projected size of US$113.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$152.3 Million by the year 2027, while Latin America will expand at a 19.4% CAGR through the analysis period.
Select Competitors (Total 44 Featured):
Amid the COVID-19 crisis, the global market for Dengue Vaccine estimated at US$340 Million in the year 2020, is projected to reach a revised size of US$962.1 Million by 2027, growing at a CAGR of 16% over the analysis period 2020-2027. Government Institutions, one of the segments analyzed in the report, is projected to record a 15.2% CAGR and reach US$490.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hospitals segment is readjusted to a revised 16.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $97.8 Million, While China is Forecast to Grow at 20.9% CAGR
The Dengue Vaccine market in the U.S. is estimated at US$97.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$193.1 Million by the year 2027 trailing a CAGR of 20.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.6% and 14.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.8% CAGR.
NGOs Segment to Record 17.6% CAGR
In the global NGOs segment, USA, Canada, Japan, China and Europe will drive the 16.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$38.8 Million in the year 2020 will reach a projected size of US$113.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$152.3 Million by the year 2027, while Latin America will expand at a 19.4% CAGR through the analysis period.
Select Competitors (Total 44 Featured):
- Biological E. Ltd.
- GlaxoSmithKline plc
- Instituto Butantan
- Panacea Biotec Ltd.
- Sanofi SA
- Takeda Pharmaceuticals Company Ltd.
- Vabiotech
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Biological E. Ltd.
- GlaxoSmithKline plc
- Instituto Butantan
- Panacea Biotec Ltd.
- Sanofi SA
- Vabiotech
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Current & Future Analysis for Dengue Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
- Table 2: World Historic Review for Dengue Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 3: World 15-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2018 & 2027
- Table 4: World Current & Future Analysis for Government Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
- Table 5: World Historic Review for Government Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 6: World 15-Year Perspective for Government Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
- Table 7: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
- Table 8: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 9: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
- Table 10: World Current & Future Analysis for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
- Table 11: World Historic Review for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 12: World 15-Year Perspective for NGOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
- UNITED STATES
- Table 13: USA Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 14: USA Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 15: USA 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- CANADA
- Table 16: Canada Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 17: Canada Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 18: Canada 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- JAPAN
- Table 19: Japan Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 20: Japan Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 21: Japan 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- CHINA
- Table 22: China Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 23: China Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 24: China 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- EUROPE
- Table 25: Europe Current & Future Analysis for Dengue Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
- Table 26: Europe Historic Review for Dengue Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 27: Europe 15-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2018 & 2027
- Table 28: Europe Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 29: Europe Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 30: Europe 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- FRANCE
- Table 31: France Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 32: France Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 33: France 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- GERMANY
- Table 34: Germany Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 35: Germany Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 36: Germany 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- ITALY
- Table 37: Italy Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 38: Italy Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 39: Italy 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- UNITED KINGDOM
- Table 40: UK Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 41: UK Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 42: UK 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- SPAIN
- Table 43: Spain Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 44: Spain Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 45: Spain 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- RUSSIA
- Table 46: Russia Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 47: Russia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 48: Russia 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- REST OF EUROPE
- Table 49: Rest of Europe Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 50: Rest of Europe Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 51: Rest of Europe 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- ASIA-PACIFIC
- Table 52: Asia-Pacific Current & Future Analysis for Dengue Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
- Table 53: Asia-Pacific Historic Review for Dengue Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 54: Asia-Pacific 15-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2018 & 2027
- Table 55: Asia-Pacific Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 56: Asia-Pacific Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 57: Asia-Pacific 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- AUSTRALIA
- Table 58: Australia Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 59: Australia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 60: Australia 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- INDIA
- Table 61: India Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 62: India Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 63: India 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- SOUTH KOREA
- Table 64: South Korea Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 65: South Korea Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 66: South Korea 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- REST OF ASIA-PACIFIC
- Table 67: Rest of Asia-Pacific Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 68: Rest of Asia-Pacific Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 69: Rest of Asia-Pacific 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- LATIN AMERICA
- Table 70: Latin America Current & Future Analysis for Dengue Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
- Table 71: Latin America Historic Review for Dengue Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 72: Latin America 15-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2018 & 2027
- Table 73: Latin America Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 74: Latin America Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 75: Latin America 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- ARGENTINA
- Table 76: Argentina Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 77: Argentina Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 78: Argentina 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- BRAZIL
- Table 79: Brazil Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 80: Brazil Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 81: Brazil 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- MEXICO
- Table 82: Mexico Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 83: Mexico Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 84: Mexico 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- REST OF LATIN AMERICA
- Table 85: Rest of Latin America Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 86: Rest of Latin America Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 87: Rest of Latin America 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- MIDDLE EAST
- Table 88: Middle East Current & Future Analysis for Dengue Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
- Table 89: Middle East Historic Review for Dengue Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 90: Middle East 15-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2018 & 2027
- Table 91: Middle East Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 92: Middle East Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 93: Middle East 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- IRAN
- Table 94: Iran Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 95: Iran Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 96: Iran 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- ISRAEL
- Table 97: Israel Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 98: Israel Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 99: Israel 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- SAUDI ARABIA
- Table 100: Saudi Arabia Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 101: Saudi Arabia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 102: Saudi Arabia 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- UNITED ARAB EMIRATES
- Table 103: UAE Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 104: UAE Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 105: UAE 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- REST OF MIDDLE EAST
- Table 106: Rest of Middle East Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 107: Rest of Middle East Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 108: Rest of Middle East 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- AFRICA
- Table 109: Africa Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
- Table 110: Africa Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
- Table 111: Africa 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
- Total Companies Profiled: 44
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Biological E. Ltd.
- GlaxoSmithKline plc
- Instituto Butantan
- Panacea Biotec Ltd.
- Sanofi SA
- Takeda Pharmaceuticals Company Ltd.
- Vabiotech
Note: Product cover images may vary from those shown
